Cowen analyst Steve Scala called AstraZeneca a European Best Idea as its product momentum and high relative growth can allow it to outperform on an extended basis if management can continue to execute. Its low U.S. exposure makes the company less vulnerable to election rhetoric. Scala reiterated his Outperform rating and $55 price target on AstraZeneca shares.

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Cowen... To see the rest of the story go to thefly.com. See Story Here